Working to Eradicate Gynecologic Cancers

Francesco Raspagliesi, MD

Professor
Fondazione IRCCS Istituto Nazionale Tumori -Milan
Via Giacomo Venezian, 1
Milan Italy 20133

Papers:
4 - Seminal Abstract A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 138 - Scientific Plenary Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer Questions & Panel Discussion